Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastati

Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal

cancer: a meta-analysis

Wang Ming;Zheng Xiaofeng;Ruan Xiaojiao;Ye Bailiang;Cai Long;Lin Feizhuan;Tu Jinfu

【期刊名称】《中华医学杂志（英文版）》 【年(卷),期】2014(127)003

【摘要】Background What benefits and toxicities patients acquire from the use of bevacizumab combined with first-line chemotherapy remains controversial.This study was performed to evaluate the efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic

colorectal

cancer

(mCRC).Methods

Cochrane studies

Several

databases,including searched

up

to

PubMed,Embase,and April

30,2013.Eligible

Library,were were

only

randomized,controlled trials (RCTs) with a direct comparison between mCRC patients treated with and without bevacizumab.Overall risk ratio (RR),hazard ratio (HR),odds ratio (OR),and 95％ confidence intervals (CO were calculated employing fixed or random-effects models depending on the heterogeneity of the included trials.Results Six RCTs,including 1582 patients in chemotherapy plus bevacizumab group and 1484 patients

in

chemotherapyalone

group,were

included.Overall,the

addition of bevacizumab to first-line chemotherapy increased overall response rate (ORR) by 4.5％,prolonged both progression-free survival